PMV Pharmaceuticals, Inc. carries a market capitalization of 69.86M, placing it among publicly traded companies globally. Its enterprise value stands at -27.81M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 69.86M |
| Enterprise Value | -27.81M |
PMV Pharmaceuticals, Inc. currently has 53.33M shares outstanding.
| Shares Outstanding | 53.33M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.14 |
| P/TBV Ratio | 0.74 |
| P/FCF Ratio | -0.87 |
| P/OCF Ratio | -0.87 |
PMV Pharmaceuticals, Inc. maintains a current ratio of 11.14, meaning it holds 11.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 11.14 |
| Quick Ratio | 10.88 |
| Debt / Equity | 0.33 |
| Debt / EBITDA | 0.00 |
| Interest Coverage | N/A |
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -58.65 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
| Income Tax | 25,000.00 |
| Effective Tax Rate | N/A |
PMV Pharmaceuticals, Inc.'s stock has gained approximately 3.14961% over the past 52 weeks. The 50-day moving average sits at 1.23, while the 200-day moving average is 1.30.
| Beta (5Y) | N/A |
| 52-Week Price Change | 3.14961% |
| 50-Day Moving Average | 1.23 |
| 200-Day Moving Average | 1.30 |
| Average Volume (20 Days) | N/A |
EBITDA reached -83.53M, while operating income came in at -83.66M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -83.66M |
| Pretax Income | -78.32M |
| Net Income | -78.34M |
| EBITDA | -83.53M |
| EBIT | -83.66M |
| Earnings Per Share (EPS) | -1.48 |
PMV Pharmaceuticals, Inc. holds 93.55M in cash and equivalents against 293,000.00 in total debt, resulting in a net debt position of -39.13M. Total book value stands at -464.49M, with working capital of 87.19M providing operational flexibility.
| Cash & Cash Equivalents | 93.55M |
| Total Debt | 293,000.00 |
| Net Debt | -39.13M |
| Equity (Book Value) | -464.49M |
| Book Value Per Share | -8.80 |
| Working Capital | 87.19M |
PMV Pharmaceuticals, Inc. produced -74.99M in operating cash flow over the past twelve months. After subtracting -25,000.00 in capital expenditures, free cash flow totaled -75.01M - equivalent to -1.42 per share.
| Operating Cash Flow | -74.99M |
| Capital Expenditures | -25,000.00 |
| Free Cash Flow | -75.01M |
| FCF Per Share | -1.42 |
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.76 |
| FCF Yield | -114.55 |
PMV Pharmaceuticals, Inc. posts an Altman Z-Score of -3.94, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -3.94 |